4 completed, 1 active not recruiting, 1 unknown, 1 withdrawn. 4 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Stage II Prostate Adenocarcinoma: new trials by email Literature Review of Stage II Prostate Adenocarcinoma trials Research Report on Stage II Prostate Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Bicalutamide, Laboratory Biomarker Analysis, Questionnaire Administration - Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma | Phase 2 | Withdrawn | Mayo Clinic | 2017-06-27 | 2019-01-22 | |
| Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog - Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 90 | 2017-06-20 | 2026-08-10 |
| 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis - Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma | Phase 2 | Completed | Andrei Iagaru | 44 | 2017-04-10 | 2023-12-12 |
| 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery 68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET) - Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma | Phase 2 / Phase 3 | Completed | Andrei Iagaru | 74 | 2016-04-18 | 2022-03-04 |
| Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer Radiation Therapy Treatment Planning and Simulation, SBRT - Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma | Not applicable | Completed | University of Wisconsin, Madison | 115 | 2015-07-24 | 2026-10-13 |
| PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397 - Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma | Phase 1 | Completed | Barbara Ann Karmanos Cancer Institute | 8 | 2015-06-01 | 2020-10-06 |
| Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy - Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer | Not applicable | Unknown | University of Southern California | 24 | 2015-05-12 | 2022-12-12 |
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Magnetic Resonance Spectroscopy (2) · Radiosurgery (2) · Abiraterone Acetate (1) · Androgen Antagonists (1) · BAY 86-7548 (1) · Gonadotropin-Releasing Hormone (1) · Prednisone (1) · Radiation (1) · Radiotherapy (1) · Raloxifene Hydrochloride (1) · apalutamide (1) · bicalutamide (1) · deltacortene (1) · gallium 68 PSMA-11 (1) · pexidartinib (1)
Andrei Iagaru (2) · Barbara Ann Karmanos Cancer Institute (1) · Mayo Clinic (1) · Rutgers, The State University of New Jersey (1) · University of Southern California (1) · University of Wisconsin, Madison (1)
United States (6)
Andrei Iagaru (2) · Elisabeth I. Heath, M.D. (1) · Erik Castle (1) · Leslie Ballas (1) · Saum Ghodoussipour, MD (1) · Zachary Morris (1)
PMID 30605751, PMID 34406051, PMID 37179035, PMID 37555901
P30CA014089 (1), P30CA015083 (1), P30CA022453 (1), P30CA072720 (1)